M Sherman

Summary

Affiliation: University of Toronto
Country: Canada

Publications

  1. ncbi What is the long-term efficacy of percutaneous ethanol injection for small hepatocellular carcinoma?
    Morris Sherman
    University of Toronto, ON, Canada
    Nat Clin Pract Gastroenterol Hepatol 3:78-9. 2006
  2. ncbi AASLD single-topic research conference on hepatocellular carcinoma: Conference proceedings
    Morris Sherman
    University of Toronto, Toronto, Canada
    Hepatology 40:1465-73. 2004
  3. ncbi Screening for hepatocellular carcinoma
    Morris Sherman
    University of Toronto and Toronto General Hospital, 200 Elizabeth Street, Toronto, Ont, Canada M5G 2C4
    Best Pract Res Clin Gastroenterol 19:101-18. 2005
  4. ncbi Why adefovir is not yet available in Canada
    Morris Sherman
    Department of Medicine, University of Toronto, UHN, Toronto, Canada
    Can J Gastroenterol 20:694-6. 2006
  5. ncbi Hepatocellular carcinoma: epidemiology, risk factors, and screening
    Morris Sherman
    Department of Medicine, University Health Network, Toronto, Canada
    Semin Liver Dis 25:143-54. 2005
  6. ncbi Clinical recommendations for the use of recombinant human erythropoietin in patients with hepatitis C virus being treated with ribavirin
    Morris Sherman
    Toronto General Hospital, University of Toronto, Toronto, Canada
    Can J Gastroenterol 20:479-85. 2006
  7. ncbi Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy
    M Sherman
    Toronto General Hospital, 200 Elizabeth St, Toronto, Ontario, M5G 2C4 Canada
    Gut 55:1631-8. 2006
  8. ncbi Predicting survival in hepatitis B
    M Sherman
    University of Toronto and University Health Network, Toronto General Hospital, 200 Elizabeth St, Toronto, Ontario M5G 2C4, Canada
    Gut 54:1521-3. 2005
  9. ncbi Hepatocellular carcinoma: New and emerging risks
    Morris Sherman
    Department of Medicine, University of Toronto and University Health Network, Toronto, ON M5N 2N2, Canada
    Dig Liver Dis 42:S215-22. 2010
  10. ncbi Personal view: the management of chronic hepatitis B infection
    M Sherman
    Toronto General Hospital, Canada
    Aliment Pharmacol Ther 23:857-69. 2006

Detail Information

Publications62

  1. ncbi What is the long-term efficacy of percutaneous ethanol injection for small hepatocellular carcinoma?
    Morris Sherman
    University of Toronto, ON, Canada
    Nat Clin Pract Gastroenterol Hepatol 3:78-9. 2006
  2. ncbi AASLD single-topic research conference on hepatocellular carcinoma: Conference proceedings
    Morris Sherman
    University of Toronto, Toronto, Canada
    Hepatology 40:1465-73. 2004
  3. ncbi Screening for hepatocellular carcinoma
    Morris Sherman
    University of Toronto and Toronto General Hospital, 200 Elizabeth Street, Toronto, Ont, Canada M5G 2C4
    Best Pract Res Clin Gastroenterol 19:101-18. 2005
    ..This should at minimum include short interval follow-up with CT scans and MRI's...
  4. ncbi Why adefovir is not yet available in Canada
    Morris Sherman
    Department of Medicine, University of Toronto, UHN, Toronto, Canada
    Can J Gastroenterol 20:694-6. 2006
  5. ncbi Hepatocellular carcinoma: epidemiology, risk factors, and screening
    Morris Sherman
    Department of Medicine, University Health Network, Toronto, Canada
    Semin Liver Dis 25:143-54. 2005
    ..Negative results do not exclude the possibility of cancer and further follow-up is necessary...
  6. ncbi Clinical recommendations for the use of recombinant human erythropoietin in patients with hepatitis C virus being treated with ribavirin
    Morris Sherman
    Toronto General Hospital, University of Toronto, Toronto, Canada
    Can J Gastroenterol 20:479-85. 2006
    ....
  7. ncbi Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy
    M Sherman
    Toronto General Hospital, 200 Elizabeth St, Toronto, Ontario, M5G 2C4 Canada
    Gut 55:1631-8. 2006
    ..The management of patients with chronic hepatitis C who have relapsed or failed to respond to interferon based therapies is an important issue facing hepatologists...
  8. ncbi Predicting survival in hepatitis B
    M Sherman
    University of Toronto and University Health Network, Toronto General Hospital, 200 Elizabeth St, Toronto, Ontario M5G 2C4, Canada
    Gut 54:1521-3. 2005
  9. ncbi Hepatocellular carcinoma: New and emerging risks
    Morris Sherman
    Department of Medicine, University of Toronto and University Health Network, Toronto, ON M5N 2N2, Canada
    Dig Liver Dis 42:S215-22. 2010
    ..In addition to the common causes of liver disease that are recognized to be causes of HCC non-alcoholic fatty liver disease and possibly diabetes are newly emerging risk factors...
  10. ncbi Personal view: the management of chronic hepatitis B infection
    M Sherman
    Toronto General Hospital, Canada
    Aliment Pharmacol Ther 23:857-69. 2006
    ..Although therapy with combinations of nucleoside analogues has not been investigated to any extent, this is the only way to reduce the emergence or resistance, and studies are urgently needed...
  11. ncbi Approaches to the diagnosis of hepatocellular carcinoma
    Morris Sherman
    Department of Medicine, University of Toronto and University Health Network, Toronto General Hospital, 200 Elizabeth Street, Toronto, Ontario, M5G 2C4, Canada
    Curr Gastroenterol Rep 7:11-8. 2005
    ..The diagnostic difficulties are presented, with examples of diagnostic algorithms that may be helpful in managing these patients...
  12. ncbi The management of chronic viral hepatitis: a Canadian consensus conference 2004
    Morris Sherman
    University of Toronto, Toronto, Ontario, Canada
    Can J Gastroenterol 18:715-28. 2004
    ..The present document is meant to be used by practitioners and other health care providers, including public health staff and others not directly involved in patient care...
  13. ncbi Chronic hepatitis C and screening for hepatocellular carcinoma
    Morris Sherman
    Department of Medicine, University of Toronto, Toronto General Hospital, 200 Elizabeth Street, Toronto, ON M5G 2C4, Canada
    Clin Liver Dis 10:735-52. 2006
    ..This benefits patients with hepatitis C and other liver diseases because more organs become available for treatment of other liver diseases...
  14. ncbi Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks
    Morris Sherman
    Department of Medicine, Toronto General Hospital, Toronto, Ontario, Canada
    Hepatology 48:99-108. 2008
    ..CONCLUSION: Through 96 weeks of treatment, 1 mg entecavir resulted in continued clinical benefit in lamivudine-refractory HBeAg-positive chronic hepatitis B patients with a safety profile comparable to lamivudine...
  15. ncbi The resurrection of alphafetoprotein
    Morris Sherman
    Department of Medicine, University of Toronto and University Health Network, Toronto, Canada
    J Hepatol 52:939-40. 2010
    ..CONCLUSION: The data presented support the use of AFP response seen after locoregional therapy as an ancillary method of assessing tumour response and survival, as well as an early objective screening tool for progression by imaging...
  16. ncbi Hepatocellular carcinoma: screening and staging
    Morris Sherman
    Department of Medicine, University of Toronto, Toronto General Hospital, 585 University Avenue, Toronto, ON M5G 2N2, Canada
    Clin Liver Dis 15:323-34, vii-x. 2011
    ..With new molecular targeted agents coming, it is critical that studies are performed in patients stratified by stage into homogeneous groups. Because it is linked with therapy, the BCLC is ideally suited to this purpose...
  17. ncbi Modern approach to hepatocellular carcinoma
    Morris Sherman
    University of Toronto, Toronto, ON, Canada
    Curr Gastroenterol Rep 13:49-55. 2011
    ..These techniques are now being used to identify new potential targets for therapy, and hold great promise for the future...
  18. ncbi Management of chronic hepatitis C: consensus guidelines
    Morris Sherman
    Department of Medicine, University of Toronto, Toronto General Hospital, Toronto, Ontario, Canada
    Can J Gastroenterol 21:25C-34C. 2007
    ..The document should be read in conjunction with the previous document to identify changes. Some recommendations made in the previous document remain and are not discussed here...
  19. ncbi Surveillance for hepatocellular carcinoma and early diagnosis
    Morris Sherman
    Department of Medicine, University of Toronto, Toronto, Ontario, Canada
    Clin Liver Dis 11:817-37, viii. 2007
    ..Such an approach has the potential to convert HCC from a disease in which incidence more or less equaled mortality to one in which cure is frequently possible...
  20. ncbi Management of chronic hepatitis B: consensus guidelines
    Morris Sherman
    Department of Medicine, University of Toronto, Toronto General Hospital, Toronto, Canada
    Can J Gastroenterol 21:5C-24C. 2007
    ..The present document should be read in conjunction with the companion document on the management of chronic hepatitis C...
  21. ncbi Vinyl chloride and the liver
    Morris Sherman
    Department of Medicine, University of Toronto, Rm NCSB 11C 1252, 585 University Avenue, Toronto, Ont, Canada M5G 2N2
    J Hepatol 51:1074-81. 2009
    ..However, based on the available data the hypothesis that vinyl chloride causes or contributes to the development of hepatocellular carcinoma remains unproven...
  22. ncbi Hepatocellular carcinoma: epidemiology, surveillance, and diagnosis
    Morris Sherman
    Department of Medicine, University of Toronto and University Health Network, Toronto, Canada
    Semin Liver Dis 30:3-16. 2010
    ..An algorithm has been developed that allows for diagnosis of these lesions. Very early HCC lesions have high cure rates with appropriate treatment. If all these factors are in place most HCCs can be cured...
  23. ncbi Exploring differences in response to treatment with peginterferon alpha 2a (40kD) and ribavirin in chronic hepatitis C between genotypes 2 and 3
    J Powis
    Department of Medicine, University of Toronto, Toronto, ON, Canada
    J Viral Hepat 15:52-7. 2008
    ..027). There is significant interaction between cirrhosis and genotype 3 leading to a poor antiviral response in such patients requiring an alternate management strategy. This finding should be confirmed in a larger population...
  24. ncbi Clinical trial: exposure to ribavirin predicts EVR and SVR in patients with HCV genotype 1 infection treated with peginterferon alpha-2a plus ribavirin
    V G Bain
    Department of Medicine, University of Alberta, Edmonton, AB, Canada
    Aliment Pharmacol Ther 28:43-50. 2008
    ..The impact of reduced drug exposure on outcomes in patients with chronic hepatitis C has not been determined in routine clinical practice...
  25. ncbi Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection
    Hwai I Yang
    Genomics Research Center, Academia Sinica, Graduate Institute of Epidemiology, College of Public Health and Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Toronto, Ontario, Canada
    J Clin Oncol 28:2437-44. 2010
    ..This study aimed to develop nomograms for predicting hepatocellular carcinoma risk in patients with chronic hepatitis B...
  26. ncbi Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses
    Gloria Woo
    Toronto Health Economics and Technology Assessment Collaborative, University of Toronto, Toronto, Ontario, Canada
    Gastroenterology 139:1218-29. 2010
    ..We evaluated the relative efficacies of the first 12 months of CHB treatments...
  27. ncbi Management of solitary 1 cm to 2 cm liver nodules in patients with compensated cirrhosis: a decision analysis
    Karen E Bremner
    Toronto General Research Institute, Toronto General Hospital, University Health Network, Toronto, Ontario, Canada
    Can J Gastroenterol 21:491-500. 2007
    ..Alternative strategies are immediate treatment or observation until disease progression occurs...
  28. ncbi Epidemiology of hepatocellular carcinoma
    Morris Sherman
    Department of Medicine, University of Toronto, Toronto, Ont, Canada morris sherman uhn on ca
    Oncology 78:7-10. 2010
    ..Therefore, the epidemiology of HCC parallels the epidemiology of chronic hepatitis B and hepatitis C. Whereas in Japan the peak of HCC incidence may have passed, elsewhere HCC continues to increase in incidence...
  29. ncbi Surveillance for hepatocellular carcinoma
    M Sherman
    University of Toronto and University Health Network, Toronto, Ontario, Canada
    Semin Oncol 28:450-9. 2001
    ..Nonetheless, surveillance is recommended in order to identify patients with small HCCs, who can be entered into trials of therapy of these tumors...
  30. ncbi Resection of hepatocellular carcinoma without preoperative tumor biopsy
    I Levy
    Department of Medicine, Toronto General Hospital, Toronto, Canada
    Ann Surg 234:206-9. 2001
    ..However, in a subgroup of patients with lesions less than 3 cm, particularly those with alpha-fetoprotein levels less than 100 ng/mL, there is a higher false-positive diagnostic rate, and tumor biopsy should be considered...
  31. ncbi Surveillance of hepatocellular carcinoma: we must do better
    Morris Sherman
    University of Toronto, Toronto, Ontario, Canada
    Am J Med 121:89-90. 2008
  32. ncbi Non-alcoholic fatty liver disease in HIV infection associated with altered hepatic fatty acid composition
    Bianca M Arendt
    University Health Network, Dept of Medicine, Toronto, Ontario, Canada
    Curr HIV Res 9:128-35. 2011
    ..Changes may be due to impaired FA metabolism or suboptimal n-3 PUFA intake. The potential role of n-3 PUFA (e.g. fish oil) to treat or prevent HIV/NAFLD warrants further investigation...
  33. ncbi Optimizing management strategies in special patient populations
    Morris Sherman
    University of Toronto and University Health Network, Toronto General Hospital 9N-981, 200 Elizabeth Street, Toronto, Ontario M5G 2C4, Canada
    Am J Gastroenterol 101:S26-31. 2006
    ..In patients at high risk of HCC, screening regimes may be effective. Furthermore, there is an increasing body of evidence indicating that effective suppression of viral replication may be associated with a reduced risk of HCC...
  34. ncbi Strategies for managing coinfection with hepatitis B virus and HIV
    Morris Sherman
    University of Toronto, University Health Network, Toronto, ON, Canada
    Cleve Clin J Med 76:S30-3. 2009
    ..HBV DNA levels should be monitored every 3 months; the frequency can be extended to every 6 months once the viral load becomes stable or undetectable...
  35. ncbi Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma
    Mariana Capurro
    Division of Molecualr and Cell Biology, Sunnybrook and Women's College Health Sciences Center and Deaprtment of Medical Biophysics, University of Toronto, Ontario, Canada
    Gastroenterology 125:89-97. 2003
    ..The simultaneous determination of GPC3 and AFP may significantly increase the sensitivity for diagnosis of HCC...
  36. ncbi Screening and treatment for hepatocellular carcinoma
    Morris Sherman
    Department of Medicine, University of Toronto and Toronto General Hospital, EN9 223, 200 Elizabeth Street, Toronto, Ontario M5G 2C4, Canada
    Gastroenterol Clin North Am 33:671-91, xi. 2004
    ..For patients with suitable lesions, liver transplantation offers the best form of therapy. Chemoembolization offers increased survival over no therapy. Several experimental therapies are being investigated...
  37. ncbi Outcome of small (10-20 mm) arterial phase-enhancing nodules seen on triphasic liver CT in patients with cirrhosis or chronic liver disease
    Yuji Takayama
    Division of Abdominal Imaging, Department of Medical Imaging, University Health Network and Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada
    Am J Gastroenterol 100:1523-8. 2005
    ..Serial CT is useful to guide management in these patients. Growth of small arterial phase-enhancing nodules can be used as an indicator that the nodule should be treated as hepatocellular carcinoma...
  38. ncbi Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B
    Morris Sherman
    Department of Medicine, Toronto General Hospital, Toronto, Ontario, Canada
    Gastroenterology 130:2039-49. 2006
    ..In preclinical and phase II studies, entecavir demonstrated potent antiviral activity against lamivudine-resistant HBV...
  39. ncbi Nutritional assessment and hepatic fatty acid composition in non-alcoholic fatty liver disease (NAFLD): a cross-sectional study
    Johane P Allard
    The University of Toronto and The University Health Network, The Toronto General Hospital, 200 Elizabeth Street, 9N 973, Toronto, Ont, Canada M5G 2C4
    J Hepatol 48:300-7. 2008
    ..Low hepatic n-6 and n-3 polyunsaturated fatty acid (PUFA) may contribute to steatosis and steatohepatitis and can be affected by diet and oxidative stress...
  40. ncbi Pathogenesis and screening for hepatocellular carcinoma
    Morris Sherman
    Department of Medicine, University of Toronto, Canada
    Clin Liver Dis 8:419-43, viii. 2004
    ..This article attempts to bring some rigor to the understanding of hepatocellular carcinoma...
  41. ncbi Risk of hepatocellular carcinoma in hepatitis B and prevention through treatment
    Morris Sherman
    University of Toronto, University Health Network, Toronto, ON, Canada
    Cleve Clin J Med 76:S6-9. 2009
    ..Viral suppression with continuous lamivudine therapy reduces the risk of complications and delays progression of liver disease as long as response is maintained...
  42. ncbi Percutaneous ethanol injection of unresectable medium-to-large-sized hepatomas using a multipronged needle: efficacy and safety
    C S Ho
    Department of Medical Imaging, University of Toronto, University Health Network and Mt Sinai Hospital, Toronto, Canada
    Cardiovasc Intervent Radiol 30:241-7. 2007
    ..PEI with a multipronged needle is a new, safe, and efficacious method in treating medium-to-large-sized hepatocellular carcinoma under conscious sedation. Its survival benefits require further investigations...
  43. ncbi Hepatic fatty acid composition differs between chronic hepatitis C patients with and without steatosis
    Bianca M Arendt
    University Health Network, Department of Medicine, Toronto, M5G 2C4 Ontario, Canada
    J Nutr 139:691-5. 2009
    ..Oxidative stress or nutritional status does not seem to play a predominant role for development of steatosis in CHC...
  44. ncbi Needle tract seeding after radiofrequency ablation of hepatic tumors
    Jeffrey D Jaskolka
    Department of Medical Imaging, University Health Network and Mount Sinai Hospital, 600 University Avenue, Suite 1225, Toronto, ON, Canada, M5G 1X5
    J Vasc Interv Radiol 16:485-91. 2005
    ..5% to 2.8%. Specific risk factors identified in this study include treatment of subcapsular lesions, patients treated in multiple sessions, and lesions requiring more than one electrode placement...
  45. ncbi Multidisciplinary Canadian consensus recommendations for the management and treatment of hepatocellular carcinoma
    M Sherman
    Department of Medicine, University of Toronto University Health Network and Canadian Liver Foundation, Toronto, ON
    Curr Oncol 18:228-40. 2011
    ..Consensus was defined as agreement by a two-thirds majority of the 17 members of the expert panel. Recommendations were subject to iterative review and modification by the expert panel until consensus could be achieved...
  46. ncbi Costs and cost-effectiveness of a universal, school-based hepatitis B vaccination program
    M Krahn
    Department of Medicine, University of Toronto, Ontario, Canada
    Am J Public Health 88:1638-44. 1998
    ..This study evaluated the costs and cost-effectiveness of a school-based grade 6 universal vaccination program against hepatitis B...
  47. ncbi HIV-positive patients with nonalcoholic fatty liver disease have a lower body mass index and are more physically active than HIV-negative patients
    Saira S Mohammed
    Department of Medicine, University Health Network, University of Toronto, 200 Elizabeth Street, Toronto, Ontario, Canada
    J Acquir Immune Defic Syndr 45:432-8. 2007
    ..To determine whether the clinical and metabolic features associated with nonalcoholic fatty liver disease (NAFLD) are similar between HIV-positive and HIV-negative male subjects...
  48. ncbi Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma
    Regina V Tse
    Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada
    J Clin Oncol 26:657-64. 2008
    ..To report outcomes of a phase I study of individualized stereotactic body radiotherapy treatment (SBRT) for unresectable hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (IHC)...
  49. ncbi Health-state utilities and quality of life in hepatitis C patients
    Christopher A K Y Chong
    Faculty of Medicine, University of Toronto, Ontario, Canada
    Am J Gastroenterol 98:630-8. 2003
    ....
  50. ncbi Diagnosis of small hepatocellular carcinoma
    Morris Sherman
    Hepatology 42:14-6. 2005
  51. ncbi Hepatocellular carcinoma: beyond screening
    Morris Sherman
    J Hepatol 39:269-71. 2003
  52. ncbi Design and endpoints of clinical trials in hepatocellular carcinoma
    Josep M Llovet
    HCC Translational Research Lab, Barcelona Clinic Liver Cancer Group, Liver Unit, Hospital Clinic, CIBERehd, Institute for Biomedical Investigations August Pi Sunyer, Villarroel 170, 08036 Barcelona, Catalonia, Spain
    J Natl Cancer Inst 100:698-711. 2008
    ..These surrogate markers may help to enrich study populations and maximize the cost-benefit ratio of trial execution. Design and conduct of phase 3 trials should be coordinated by centers with appropriate expertise in HCC...
  53. ncbi Twelve weeks of follow-up is sufficient for the determination of sustained virologic response in patients treated with interferon alpha for chronic hepatitis C
    Stefan Zeuzem
    Klinik fur Innere Medizin II, Universitatskliniken des Saarlandes, 66421 Homburg Saar, Germany
    J Hepatol 39:106-11. 2003
    ..Sensitive molecular tests may permit earlier determination of sustained virologic response following the completion of therapy in end-of-treatment responders...
  54. ncbi Radiofrequency ablation of malignant hepatic neoplasms
    Raymond P Chan
    Department of Medical Imaging, St Michael s Hospital, 30 Bond St, Toronto, ON M5B 1W8
    Can Assoc Radiol J 53:272-8. 2002
    ..To assess the safety and efficacy of radiofrequency ablation (RFA) in the treatment of malignant neoplasms of the liver...
  55. ncbi Diagnosis of Small HCC
    Jordi Bruix
    Gastroenterology 129:1364. 2005
  56. ncbi Simple clinical variables predict liver histology in hepatitis C: prospective validation of a clinical prediction model
    Joseph Romagnuolo
    Digestive Disease Center, University of South Carolina, 96 Jonathon Lucas Street, PO Box 250 327, Charleston, SC 29425, USA
    Scand J Gastroenterol 40:1365-71. 2005
    ..Absence of predictors also predicted a lack of inflammation and fibrosis. Our aim was prospectively to validate this clinical prediction model using an independent multicenter sample...
  57. ncbi Clinical utility of AFP-L3% measurement in North American patients with HCV-related cirrhosis
    Richard K Sterling
    Virginia Commonwealth University Health Systems, Richmond, Virginia, USA
    Am J Gastroenterol 102:2196-205. 2007
    ..The aim of this prospective study was to compare the clinical utility of AFP-L3% with that of total AFP in North American patients...
  58. ncbi Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study
    Norbert Brau
    Bronx Veterans Affairs VA Medical Center, Infectious Disease Section 111F, 130 West Kingsbridge Road, Bronx, NY 10468, USA
    J Hepatol 47:527-37. 2007
    ..HIV-infected patients now live longer and often have complications of liver disease, especially with hepatitis B or C virus coinfection. Limited data are available on those with hepatocellular carcinoma (HCC)...
  59. ncbi The degree of readiness of selected biomarkers for the early detection of hepatocellular carcinoma: notes from a recent workshop
    Timothy M Block
    Drexel Institute for Biotechnology and Virology Research, Drexel University College of Medicine, Doylestown, PA 18902, USA
    Cancer Biomark 4:19-33. 2008
    ..It is emphasized that only a selected set of biomarkers was considered; thus, this review is not comprehensive and not intended to review all candidate HCC biomarkers...
  60. ncbi Management of hepatocellular carcinoma
    Jordi Bruix
    , University of Barcelona, , Barcelona, Spain
    Hepatology 42:1208-36. 2005
  61. ncbi Advancing patient care: integrating new data
    Teresa L Wright
    University of California-San Francisco, and VA Medical Center 111B, San Francisco, CA 94121, USA
    Am J Gastroenterol 101:S32-9. 2006
    ..A number of issues were identified, and statements concerning possible management strategies that could be applied were developed...
  62. ncbi Hepatitis C: the juggernaut rolls on unchecked
    Morris Sherman
    Can J Gastroenterol 22:355-6. 2008